linjc16/ctgov huggingface dataset:
Clinical Characteristics, Management and Outcomes of Chinese Patients With Acute Aortic Dissection

Study Overview
=================
Brief Summary
-----------------
Data reported by the international registry of acute aortic dissection (IRAD) in not sufficient to reflect clinical characteristics of acute aortic dissection in China. Moreover, clinical characteristics of Acute aortic dissection have not evaluated to data. The aim of this study is analyze changing trend of clinical characteristics of Chinese patients with acute aortic dissection.

Detailed Description
-----------------
Acute aortic dissection is the most common aortic emergency, with an annual incidence of 3-5 cases per 100 000 population. About 50% of these patients are dead within 48 hours, if untreated. To assess the clinical manifestation, diagnosis, management, and outcomes of patients with AAD, the International Registry of Acute Aortic Dissection (IRAD) was established in 1996, and has grown to include about 2000 patients from 26 large referral centers to date. All patients from IRAD are caucasians from developed countries wiht advanced medical care, however, the proportion of Asian is very low. Data reported by the IRAD in not sufficient to reflect clinical characteristics of Acute aortic dissection in China. Clinical characteristics of Chinese patients with acute aortic dissection have not evaluated to data. The aim of this study is to analyze clinical characteristics of Chinese patients with acute aortic dissection and clinical trend of acute aortic dissection.

Official Title
-----------------
Clinical Investigation of Chinese Patients With Aortic Dissection

Conditions
-----------------
Aortic Dissection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of acute aortic dissection Type A dissection Type B dissection Retrograde type B dissection Exclusion Criteria: Aortic aneurysm Myocardial infarction Cerebral accident Active infection Unwillingness to cooperation with study procedures or follow-up visits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aorta, dissection, feature
Adjunct Episcleral Brachytherapy for PCV

Study Overview
=================
Brief Summary
-----------------
This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate response to anti-VEGF monotherapy.

Official Title
-----------------
A Double-Masked, Multi-center, Active Controlled Safety and Efficacy Study of Adjunct Episcleral Brachytherapy for Polypoid Choroidal Vasculopathy

Conditions
-----------------
Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy

Intervention / Treatment
-----------------
* Radiation: Episcleral Brachytherapy
* Drug: Aflibercept Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active PCV due to nAMD Incomplete response to anti-VEGF Received at least 3 consecutive and sequential anti-VEGF injections (no missed treatments) Ability to undergo ESB intervention Exclusion Criteria: Sub-retinal fibrosis Type I or Type II diabetes mellitus Previous therapeutic radiation to the head or neck that may have resulted in radiation dose to the retina Study eye with BCVA of worse than 20 ETDRS letters (20/400 Snellen) Fellow eye with worse BCVA than the study eye or other vision-threatening disease not eligible for treatment Receiving anti-VEGF therapy for any reason other than AMD

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ESB adjunct to IAI<br>Single ESB treatment adjunct to intravitreal aflibercept injections (IAI) | Radiation: Episcleral Brachytherapy<br>* Minimally invasive, single fraction brachytherapy<br>Drug: Aflibercept Injection<br>* Standard of Care intravitreal aflibercept injection<br>|
| Active Comparator: IAI monotherapy<br>Intravitreal aflibercept injections (IAI) | Drug: Aflibercept Injection<br>* Standard of Care intravitreal aflibercept injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Corrected Visual Acuity (BCVA) |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Corrected Visual Acuity (BCVA) |  | 24 months | 
| Central Retinal Thickness |  | 12 and 24 months | 
| Lesion size |  | 12 and 24 months |
Effect of Saccharomyces Boulardii on Indirect Hyperbilirubinemia and Phototherapy Duration in Very Low Birth Weight Infants

Study Overview
=================
Brief Summary
-----------------
Indirect hyperbilirubinemia is frequently observed in premature infants.Probiotics are favorable microorganisms that regulate the flora of the gastrointestinal system. In this study we aimed to compare the effect of S. boulardii on severity of hyperbilirubinemia and duration of phototherapy on very low birth weight infants.

Official Title
-----------------
Phase 4 Study of Saccharomyces Boulardii on Indirect Hyperbilirubinemia

Conditions
-----------------
Indirect Hyperbilirubinemia

Intervention / Treatment
-----------------
* Dietary Supplement: Reflor
* Other: serum physiologic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: very low birth weight infants Exclusion Criteria: chromosomal anomalies

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 15 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Saccharomyces boulardii<br>study group | Dietary Supplement: Reflor<br>* 5 million unit/day, first 15 day of life<br>|
| Placebo Comparator: placebo<br>serum physiologic | Other: serum physiologic<br>* 1 cc added to one feeding in a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of S. boulardii on severity of hyperbilirubinemia and phototherapy duration |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| long term effect of S.boulardii on neurodevelopmental outcome |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
indirect hyperbilirubinemia, very low birth weight infants
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.

Official Title
-----------------
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients With Acute Myeloid Leukaemia.

Conditions
-----------------
Myeloid Leukemia

Intervention / Treatment
-----------------
* Drug: AZD1152


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Relapsed or refractory AML for which no standard therapies are anticipated to result in durable remission Newly diagnosed AML who are not considered suitable for other treatments. Exclusion Criteria: Previous myeloablative therapy allogeneic bone marrow or stem cell transplantation, radiotherapy or chemotherapy within 4 weeks of first dose. Participation in any other trial with an investigational product within the previous 30 days Other active malignancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AZD1152|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety and tolerability of multiple ascending doses AZD1152 in patients with AML by assessment of AEs, vital signs, ECG parameters, clinical chemistry, haematology (including clotting parameters) and urinalysis. |  | Assessed at each visit | 
| To determine the rate of complete remission from baseline changes in bone marrow and blood myeloblast counts and recovery of normal haemopoiesis |  | Change from baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the pharmacokinetics, pharmacodynamics, efficacy, safety and tolerability |  | Assessed at each visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AML, phase I/II, AZD1152, Acute Myeloid Leukaemia
The Different Analgesic Potency of Volatile Anesthetics at Equi-MAC

Study Overview
=================
Brief Summary
-----------------
The aim of this clinical trial is to evaluate the difference of analgesic potency of sevoflurane and desflurane at equi-minimum alveolar concentration using a surgical pleth index.

Detailed Description
-----------------
Volatile anesthetics vary in their relative hypnotic potencies. Recent studies demonstrated that equi-minimum alveolar concentration of various volatile anesthetics produced different EEG-derived indices such as bispectral index. However, there was no controlled study that demonstrates the difference of analgesic potency. The aim of this clinical trial is to evaluate the difference of analgesic potency of sevoflurane and desflurane at equi-minimum alveolar concentration using a surgical pleth index.

Official Title
-----------------
The Different Analgesic Potency of Sevoflurane and Desflurane at Equi-minimum Alveolar Concentration

Conditions
-----------------
Orthopedic Disorders

Intervention / Treatment
-----------------
* Drug: Sevoflurane
* Drug: Desflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing arthroscopic shoulder surgery patients with american society of anesthesiologist physical status I, II patients aged 19-65 years patients obtaining written informed consent Exclusion Criteria: patients with a history of any psychiatric or neurological disease patients who had received any medication affecting the central nervous system patients who had received medication affecting the sympathetic or parasympathetic nervous systems patients who have not received interscalene approach brachial plexus block (refusal or failure) pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sevoflurane<br>Anesthesia was maintained with sevoflurane. | Drug: Sevoflurane<br>* Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.<br>* Other names: SEVO;|
| Experimental: Desflurane<br>Anesthesia was maintained with desflurane. | Drug: Desflurane<br>* Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.<br>* Other names: DES;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesic potency of volatile anesthetics | The analgesic potency was evaluated by surgical pleth index value | the first 60 min of maintaining a steady state 1 MAC of volatile agents |
Association Between Schizophrenia and Cancer

Study Overview
=================
Brief Summary
-----------------
A family study of the negative association betweeen schizophrenia and cancer

Conditions
-----------------
Schizophrenia, Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: schizophrenia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
PS-341 in Treating Patients With Metastatic Kidney Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic kidney cancer.

Detailed Description
-----------------
OBJECTIVES: Determine the efficacy of PS-341 in patients with metastatic renal cell carcinoma. Determine the safety of this drug in these patients. OUTLINE: This is an open-label study. Patients receive PS-341 IV over 3-5 seconds twice weekly for 2 weeks. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed at 2 weeks. PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19 months.

Official Title
-----------------
Phase II Trial of PS341 (NSC 681239) in Patients With Advanced Renal Cell Carcinoma

Conditions
-----------------
Kidney Cancer

Intervention / Treatment
-----------------
* Drug: bortezomib


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically confirmed renal cell carcinoma Metastatic disease Unidimensionally measurable disease No brain metastases PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Life expectancy: More than 3 months Hematopoietic: WBC at least 3,000/mm^3 Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin no greater than 1.5 mg/dL ALT/AST no greater than 2.5 times upper limit of normal (ULN) Renal: Creatinine no greater than 1.5 times ULN Other: No pre-existing neuropathy of grade 1 or greater No other malignancy within the past 5 years, except completely resected basal cell skin cancer, unless treated with potentially curative therapy or at low risk for recurrence Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 4 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy and recovered No concurrent biologic therapy Chemotherapy: No prior cytotoxic therapy No concurrent cytotoxic therapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: At least 4 weeks since prior major surgery Other: No other concurrent anticancer therapy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: bortezomib|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage IV renal cell cancer
Morphological and Functional Evaluation of Irvine-Gass Syndrome

Study Overview
=================
Brief Summary
-----------------
Purpose: To evaluate morphological and functional characteristics of Irvine Gass syndrome Methods: 30 patients suffering on Cystoid macular edema (CME) secondary to Cataract surgery will be observed and evaluated by fluorescein-angiography, SD-OCT, reading performance, contrast sensitivity and microperimetry in a fixed time schedule

Conditions
-----------------
Irvine Gass Syndrome

Intervention / Treatment
-----------------
* Behavioral: if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years St.p Cataract surgery able to read informed consent with fluorescein angiography and SD-OCT diagnosed Irvine Gass syndrome Exclusion Criteria: < 18 years CME of other origin diabetic macular edema

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients suffering on CME secondary to cataract surgery<br> | Behavioral: if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection<br>* if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of central retinal thickness |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase of Best corrected visual acuity |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Irvine Gass syndrome, multimodal imaging, SD-OCT, CME secondary to cataract surgery, in vivo correlation of morphology and function
Efficacy of Lappa Arctium (Homoeopathic Medicine) in Treatment of Acne Vulgaris

Study Overview
=================
Brief Summary
-----------------
Acne is one of the most common skin problems in teenagers and adolescents. There are many lesser known homoeopathic medicines which have been mentioned in the literature for treatment of acne but their potential has not been properly assessed /documented and therefore these medicines don't form a part of many prescriptions. As a part of this study,efficacy of Lappa Arctium will be studied in the treatment of Acne vulgaris

Official Title
-----------------
Efficacy of Lesser Known Homoeopathic Medicines in Acne Vulgaris - Lappa Arctium

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Drug: Lappa Arctium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females between 12 to 25 years of age Presence of inflammatory and non-inflammatory lesions Able to follow-up according to protocol Patients not taking any medication for treatment of Acne in preceding one month. Exclusion Criteria: Acne Conglobata Pregnant or Breast feeding females or females having intention of becoming pregnant Significant systemic disease Any drug/ alcohol addiction History of chronic diseases treated with medications in the preceding month which might affect acne condition and treatment outcome

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percent change in acne lesion counts from the Baseline |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in quality of life of subjects |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acne Vulgaris, Homoeopathy, Lappa Arctium